Powerful metrics provide multiple physiological assessments from a single sample
Now available using the SomaScan® 11K Assay
Obtain relevant data to advance your research.
SomaSignal Tests are for Research Use Only, and not to be used for diagnostic or patient medical management purposes. Looking for a diagnostic tool to guide patient medical treatment? Learn about our LDT SSTs.
What are RUO SomaSignal® Tests?
For simple, straightforward clinical trial monitoring
- Simple blood test enables frequent sampling
- Does not require specialized physicians/pathologists
- Simple blood draw is ideal for longitudinal studies
Physiologically meaningful assessments
- 21 SSTs provide multiple metrics from a single sample
- Relevant to cardiovascular disease, NASH, diabetes, and more
- Reporting current health state and understanding risk
Derived from just a 55-µL sample
- Simple and simultaneous sampling for all tests
- Derived from models based on proteomic signatures
- Validated against standard clinical measurement
See the technology
WebinarCorrelation of a nonalcoholic steatohepatitis proteomic test with clinical outcomes
In this webinar, Anne Minnich, PhD, biomarker consultant at Bristol Myers Squibb, presents research on the use of the new SomaSignal(TM) NASH bundle test in a recently completed clinical trial.What tests are available for research use?
Body fat %
Percent body fat
Resting energy expenditure
Calories burned at rest
Lean body mass
Total lean body mass
Glucose tolerance
Blood glucose levels following sugar intake
Liver fat
Presence/absence of excess liver fat
Visceral fat
Fat content around vital organs
CVD primary
4-year risk of heart attack, stroke, or heart failure
CVD secondary
4-year risk of heart attack, stroke, or heart failure following an initial event
Cardiorespiratory fitness
Aerobic fitness level (VO2 max)
Alcohol impact
Predicted weekly alcohol consumption
NASH: steatosis
Measures NASH-related liver steatosis
NASH: inflammation
Measures NASH-related liver inflammation
NASH: Fibrosis
Measures NASH-related Liver Fibrosis
NASH: ballooning
Measures NASH-related liver ballooning
Heart Failure reduced Ejection Fraction: 6 months
Risk of death in 6 months with stable HFrEF
Heart Failure reduced Ejection Fraction: 12 months
Risk of death in 1 year with stable HFrEF
Heart Failure preserved Ejection Fraction: 6 months
Risk of death in 6 months with stable HFpEF
Heart Failure preserved Ejection Fraction: 12 months
Risk of death in 1 year with stable HFpEF
Kidney prognosis
Risk of worsening Chronic Kidney Disease
Dementia risk
Risk of Dementia diagnosis within 20 years
Fed-fasted
Hours since last meal
How were they developed?
SomaSignal Tests are developed by analyzing thousands of proteins in thousands of patients using the SomaScan Assay. Protein signatures revealed by the SomaScan Assay are compared against standard clinical measurements in order to identify patterns of protein changes that correlate with current health status and future trajectory using machine learning. Each pattern becomes the basis for a specific SomaSignal Test. Because each SomaSignal Test is generated using a subset of the 11,000 proteins measured by the SomaScan Assay, results for all of the SomaSignal Tests can be derived from a single 55-µL blood sample.
